DrugCard Literature Screening
B2B
DrugCard provides full-regulatory compliant SaaS to help pharmacovigilance teams in pharma companies and CROs by trimming literature screening time and generating deeper insights about drug safety using sophisticated parsers and AI-tech. Having secured €500K from venture capitalists and with Google's support, our trajectory is set towards 100 customers and a projected ARR of €1.0M by 2024.
Company:DrugCards
Key features of DrugCard:● Big database of medical and scientific literature, including more than 600 local journal sites and publications from EMA, WHO, FDA, MHRA, TGA, PMDA, Swissmedic, and local Health Authorities● Automatic article translation● Support of any journals (PDFs, scanned PDFs, HTML pages)● Automatic reports and audit trails● Advanced OCR and AI technologies● GVP / FDA CFR 21 Part 11 / GAMP5 compliant